ERBB2 and cancer: Similar findings were also reported by Perez and colleagues from another of the adjuvant trastuzumab trials (16), and data from xenograft models indicated that trastuzumab may target the cancer stem cell population via a mechanism that does not require HER2 gene amplification (17).